Human ex vivo validation of the potential of Loma’s HPV-targeted immunotherapy has been published in Cancers. The study conducted in collaboration between Loma Therapeutics and Hervolution supports that Loma’s unique immunotherapy can induce strong and functional CD8+...
Loma Therapeutics was awarded for Merck’s Advance Biotech Grant for their pitch at the Nordic Stars Pitch Competition. CEO Ditte Boilesen and COO Stephanie Holstein-Rønsbo received the award on stage, which includes bioprocessing technologies and services valued at...
A substantial part of Loma Therapeutics’ pre-clinical proof of concept was published in Cancer Immunology Research. Briefly, the HPV-targeted immunotherapy underwent thorough in vitro QC to ensure expression of HPV genes and successful inactivation of E6 and E7...